lnu.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Interpretation of Serological Complement Biomarkers in Disease
Linnéuniversitetet, Fakulteten för Hälso- och livsvetenskap (FHL), Institutionen för kemi och biomedicin (KOB). Uppsala University. (Linnaeus Ctr Biomat Chem, BMC)ORCID-id: 0000-0001-7888-1571
Uppsala University.
Linnéuniversitetet, Fakulteten för Hälso- och livsvetenskap (FHL), Institutionen för kemi och biomedicin (KOB). (Linnaeus Ctr Biomat Chem, BMC)
Linnéuniversitetet, Fakulteten för Hälso- och livsvetenskap (FHL), Institutionen för kemi och biomedicin (KOB). (Linnaeus Ctr Biomat Chem, BMC)
Visa övriga samt affilieringar
2018 (Engelska)Ingår i: Frontiers in Immunology, ISSN 1664-3224, E-ISSN 1664-3224, Vol. 9, artikel-id 2237Artikel, forskningsöversikt (Refereegranskat) Published
Abstract [en]

Complement systemaberrations have been identified as pathophysiological mechanisms in a number of diseases and pathological conditions either directly or indirectly. Examples of such conditions include infections, inflammation, autoimmune disease, as well as allogeneic and xenogenic transplantation. Both prospective and retrospective studies have demonstrated significant complement-related differences between patient groups and controls. However, due to the low degree of specificity and sensitivity of some of the assays used, it is not always possible to make predictions regarding the complement status of individual patients. Today, there are three main indications for determination of a patient's complement status: (1) complement deficiencies (acquired or inherited); (2) disorders with aberrant complement activation; and (3) C1 inhibitor deficiencies (acquired or inherited). An additional indication is to monitor patients on complement-regulating drugs, an indication which may be expected to increase in the near future since there is now a number of such drugs either under development, already in clinical trials or in clinical use. Available techniques to study complement include quantification of: (1) individual components; (2) activation products, (3) function, and (4) autoantibodies to complement proteins. In this review, we summarize the appropriate indications, techniques, and interpretations of basic serological complement analyses, exemplified by a number of clinical disorders.

Ort, förlag, år, upplaga, sidor
Frontiers Media S.A., 2018. Vol. 9, artikel-id 2237
Nyckelord [en]
complement, deficiency, activation products, functional test, complement regulatory drugs
Nationell ämneskategori
Immunologi
Forskningsämne
Biomedicinsk vetenskap, Immunologi
Identifikatorer
URN: urn:nbn:se:lnu:diva-78739DOI: 10.3389/fimmu.2018.02237ISI: 000448107500001Scopus ID: 2-s2.0-85055834488OAI: oai:DiVA.org:lnu-78739DiVA, id: diva2:1261679
Tillgänglig från: 2018-11-08 Skapad: 2018-11-08 Senast uppdaterad: 2019-08-29Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextScopus

Personposter BETA

Nilsson Ekdahl, KristinaMohlin, CamillaSandholm, Kerstin

Sök vidare i DiVA

Av författaren/redaktören
Nilsson Ekdahl, KristinaMohlin, CamillaSandholm, Kerstin
Av organisationen
Institutionen för kemi och biomedicin (KOB)
I samma tidskrift
Frontiers in Immunology
Immunologi

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetricpoäng

doi
urn-nbn
Totalt: 7 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf